Feasibility study of neoadjuvant chemotherapy with docetaxel/CDGP/5-fluorouracil in resectable esophagus cancer

Feasibility study of neoadjuvant chemotherapy with docetaxel/CDGP/5-fluorouracil in resectable esophagus cancer - DNF-NAC for resectable esophagus cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014305

Enrollment

Registered

2014-06-18

Start date

2014-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophagus cancer

Interventions

Chemotherapy using docetaxel,CDGP,5-FU followed by surgical resection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically proven esophageal squamous cell carcinoma. 2) Patients who are going to undergo curative esophagectomy with 2F or 3F lymph node dissection. 3) TNM stage Ib-III 4) Performance status 0-2 ECOG 5) Tolerable function of bone marrow,liver and kidney.

Exclusion criteria

Exclusion criteria: (1) No prior chemotherapy regimen. (2) history of drug hypersensitivity. (3) active concomitant malignancy. (4) serious complications (severe heart disease, active infection) (5) pregnant or lactating females. (6) The investigator considers not suitable for the study.

Design outcomes

Primary

Measure	Time frame
Completion rate of protocol treatment	—

Secondary

Measure	Time frame
Safety Progression-free survival Overall survival R0 resection rate Operative morbidity	—

Countries

Japan

Contacts

Public ContactHiroyuki Ohnuma

Sapporo Medical University School of Medicine Department of Medical Oncology

ohnuma@sapmed.ac.jp011-611-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026